| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | COVER ARCHIVE | SEARCH |
|
|
|
||||||||
|
||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dr. Jemal is Strategic Director, Cancer Surveillance, Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, GA.
Ms. Siegel is Manager, Surveillance Information Services, Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, GA.
Dr. Ward is Managing Director, Surveillance Research, Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, GA.
Dr. Hao is Senior Epidemiologist, Surveillance Research, Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, GA.
Dr. Xu is Epidemiologist, Mortality Statistics Branch, Division of Vital Statistics, National Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, MD.
Mr. Murray is Manager, Surveillance Data Systems, Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, GA.
Dr. Thun is Vice President, Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, GA.
ABSTRACT
Each year, the American Cancer Society estimates the number of new cancer cases and deaths expected in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival based on incidence data from the National Cancer Institute, Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries and mortality data from the National Center for Health Statistics. Incidence and death rates are age-standardized to the 2000 US standard million population. A total of 1,437,180 new cancer cases and 565,650 deaths from cancer are projected to occur in the United States in 2008. Notable trends in cancer incidence and mortality include stabilization of incidence rates for all cancer sites combined in men from 1995 through 2004 and in women from 1999 through 2004 and a continued decrease in the cancer death rate since 1990 in men and since 1991 in women. Overall cancer death rates in 2004 compared with 1990 in men and 1991 in women decreased by 18.4% and 10.5%, respectively, resulting in the avoidance of over a half million deaths from cancer during this time interval. This report also examines cancer incidence, mortality, and survival by site, sex, race/ethnicity, education, geographic area, and calendar year, as well as the proportionate contribution of selected sites to the overall trends. Although much progress has been made in reducing mortality rates, stabilizing incidence rates, and improving survival, cancer still accounts for more deaths than heart disease in persons under age 85 years. Further progress can be accelerated by supporting new discoveries and by applying existing cancer control knowledge across all segments of the population.
This article has been cited by other articles:
|
|
 |
|
  K. N. Utecht and J. Kolesar Bortezomib: A novel chemotherapeutic agent for hematologic malignancies Am. J. Health Syst. Pharm., July 1, 2008; 65(13): 1221 - 1231. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Michaelson, S. E. Cotter, P. C. Gargollo, A. L. Zietman, D. M. Dahl, and M. R. Smith Management of Complications of Prostate Cancer Treatment CA Cancer J Clin, July 1, 2008; 58(4): 196 - 213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Diamond, L. Sun, A. J. Ottaviano, M. J. Joseph, and H. G. Munshi Differential growth factor regulation of N-cadherin expression and motility in normal and malignant oral epithelium J. Cell Sci., July 1, 2008; 121(13): 2197 - 2207. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Kavalerchik, D. Goff, and C. H.M. Jamieson Chronic Myeloid Leukemia Stem Cells J. Clin. Oncol., June 10, 2008; 26(17): 2911 - 2915. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Lewis, J. S. Zager, D. Yu, D. Pelaez, A. I. Riker, S. Dessureault, C. W. Cruse, D. S. Reintgen, C. A. Puleo, and V. K. Sondak Full-Thickness Grafts Procured from Skin Overlying the Sentinel Lymph Node Basin; Reconstruction of Primary Cutaneous Malignancy Excision Defects Ann. Surg. Oncol., June 1, 2008; 15(6): 1733 - 1740. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Federman and G. L. Federman Color Atlas of Melanocytic Lesions of the Skin JAMA, May 28, 2008; 299(20): 2449 - 2449. [Full Text] [PDF]
|
|
|
|
|
|
S. Halabi, N. J. Vogelzang, A. B. Kornblith, S.-S. Ou, P. W. Kantoff, N. A. Dawson, and E. J. Small Pain Predicts Overall Survival in Men With Metastatic Castration-Refractory Prostate Cancer J. Clin. Oncol., May 20, 2008; 26(15): 2544 - 2549. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Moore, D. L. Persons, J. A. Sosman, D. Bobadilla, V. Bedell, D. D. Smith, S. R. Wolman, R. J. Tuthill, J. Moon, V. K. Sondak, et al. Detection of Copy Number Alterations in Metastatic Melanoma by a DNA Fluorescence In situ Hybridization Probe Panel and Array Comparative Genomic Hybridization: A Southwest Oncology Group Study (S9431) Clin. Cancer Res., May 15, 2008; 14(10): 2927 - 2935. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. G. Spector, A. J. Hooten, and J. A. Ross Ontogeny of Gene Expression: A Changing Environment for Malignancy Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1021 - 1023. [Full Text] [PDF]
|
|
|
|
|
|
S. E. Pories, D. Zurakowski, R. Roy, C. C. Lamb, S. Raza, A. Exarhopoulos, R. G. Scheib, S. Schumer, C. Lenahan, V. Borges, et al. Urinary Metalloproteinases: Noninvasive Biomarkers for Breast Cancer Risk Assessment Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1034 - 1042. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Levin, D. A. Lieberman, B. McFarland, R. A. Smith, D. Brooks, K. S. Andrews, C. Dash, F. M. Giardiello, S. Glick, T. R. Levin, et al. Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology CA Cancer J Clin, May 1, 2008; 58(3): 130 - 160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Ajani, K. A. Winter, L. L. Gunderson, J. Pedersen, A. B. Benson III, C. R. Thomas Jr, R. J. Mayer, M. G. Haddock, T. A. Rich, and C. Willett Fluorouracil, Mitomycin, and Radiotherapy vs Fluorouracil, Cisplatin, and Radiotherapy for Carcinoma of the Anal Canal: A Randomized Controlled Trial JAMA, April 23, 2008; 299(16): 1914 - 1921. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Melisi, S. Ishiyama, G. M. Sclabas, J. B. Fleming, Q. Xia, G. Tortora, J. L. Abbruzzese, and P. J. Chiao LY2109761, a novel transforming growth factor {beta} receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis Mol. Cancer Ther., April 1, 2008; 7(4): 829 - 840. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Mulshine Commentary: Lung Cancer Screening--Progress or Peril Oncologist, April 1, 2008; 13(4): 435 - 438. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | COVER ARCHIVE | SEARCH |
